Shopping Cart
- Remove All
- Your shopping cart is currently empty
Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | Inquiry | Backorder | |
5 mg | Inquiry | Backorder |
Description | Bifikafusp alfa (L19-IL2) is an immunotherapeutic fusion protein combining human L19 antibodies with the cytokine interleukin 2 (IL2), targeting the extra domain B (EDB) of fibronectin, and has demonstrated anticancer activity [1]. |
In vivo | Bifikafusp alfa (1.43 and 4.29 MIU/kg; i.p.; daily; for 10 days; female NMRI nude mice MiaPaca-A2 xenografts) exhibited antitumor activity against established pancreatic cancer [1]. |
Alias | L19-IL2 |
Cas No. | 1957239-90-5 |
Storage | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.